Peer-influenced content. Sources you trust. No registration required. This is HCN.
Epoch Health
Viatris recalled one lot of Xanax XR 3-mg extended-release tablets after failed dissolution testing, with the FDA classifying the action as Class II and reporting no adverse events to date.
Family Medicine/General Practice April 29th 2026
Conexiant
“Semaglutide and, to a lesser extent, liraglutide were associated with significantly lower risk of worsening mental illness.” – Lead Study Researcher Heidi Taipale, PhD, University of Eastern Finland and Niuvanniemi Hospital
Endocrinology, Diabetes, Metabolism April 14th 2026
The authors suggest that an effective, smartphone-delivered CBT program could expand access to first-line treatment for GAD—particularly in settings where traditional therapy is difficult to obtain.
Psychiatry March 18th 2026
The Canadian Journal of Psychiatry
“The prevalence of internalizing problems increased more rapidly among Canadians who used cannabis compared to those who do not.” — Study authors
Medical Xpress
The chemical pattern in the brain suggests nutritional approaches—like appropriate choline supplementation—may help restore brain chemistry and improve outcomes for patients.
Family Medicine/General Practice November 18th 2025
Medical News Today (MNT)
Patients benefit from understanding that anxiety medications work differently – some provide immediate relief while others build effectiveness over weeks, allowing for informed discussions about treatment preferences and lifestyle considerations.
Clinical Pharmacology July 23rd 2025